In a 6-month randomized, open-label, controlled study, 95 T2D subjects (BMI ≥ 27 kg/m2, hemoglobin A1c 8%) on metformin monotherapy were randomized to receive the GLP-1 RA liraglutide or to remain on metformin. The gene discussed is GCG; the disease is type 2 diabetes mellitus.